Duchenne Muscular Dystrophy Treatment Market Size & Share, by Therapy (Exon Skipping Approach, Mutation Suppression); Treatment (Corticosteroids, Pain Management Drugs, Physical Therapy); Distribution Channel (Hospitals, Specialty Clinics, Surgical Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3814
  • Published Date: Aug 22, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Duchenne Muscular Dystrophy Treatment Market size was valued at USD 3.12 billion in 2023 and is expected to exceed USD 13.3 billion by 2036, expanding at over 11.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of duchenne muscular dystrophy treatment is assessed at USD 3.41 billion. Duchenne muscular dystrophy is an inherited muscular disorder, which results in extreme weakness in muscles. The growth of the market can be attributed to the increasing demand for treatment for Duchenne muscular dystrophy or DMD, along with rising research activities for the development of new treatment methods. Moreover, the growing prevalence of muscular disorders, backed by poor lifestyle and lack of physical activities, are estimated to boost the market growth. According to the data by the World Health Organization (WHO), 1.71 billion people suffer from musculoskeletal disorders. DMD is a type of myositis, which is why, it has no cure. The growing demand for myositis treatment, is anticipated to positively affect the market growth.

Furthermore, DMD is a rare genetic disorder, mostly prevalent amongst males. According to the National Organization of Rare Disorders (NORD), DMD affects approximately 1 in every 3,500 male births worldwide. The high share of male population, in the total global population is projected to promote the global market growth. In 2020, 50.415% of the global population, i.e., 3.907 billion people were male, as per the statistics by the World Bank.

In addition to this, the absence of any permanent treatment for this disorder, along with the growing investment in the R&D activities is estimated to boost the market growth.  According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.


Get more information on this report: Request Free Sample PDF

Duchenne Muscular Dystrophy Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Prevalence of Musculoskeletal Disorders
  • High Share of Male Population Globally
  • Increasing R&D Activities in Healthcare Sector

Challenges

  • Difficult Diagnosis of the Disease
  • Lack of Health Awareness amongst People in Undeveloped Regions

Duchenne Muscular Dystrophy Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

11.8%

Base Year Market Size (2023)

USD 3.12 billion

Forecast Year Market Size (2036)

USD 13.3 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
 
Get more information on this report: Request Free Sample PDF

Duchenne Muscular Dystrophy Treatment Segmentation

The market is segmented by treatment into corticosteroids, pain management drugs, physical therapy, and others, out of which, the pain management drugs segment is anticipated to hold the largest revenue share in the market over the forecast period. This can be accredited to the high demand for pain management drugs, as DMD can be extremely painful. Moreover, it is primarily diagnosed in kids of age between 3-6 years, who have a lower threshold for pain. Such factors are estimated to further boost the segment growth.

Our in-depth analysis of the global market includes the following segments

            By Therapy

  • Exon Skipping Approach
  • Mutation Suppression
  • Others

            By Treatment

  • Corticosteroids
  • Pain Management Drugs
  • Physical Therapy
  • Others

            By Distribution Channel

  • Hospitals
  • Specialty Clinics
  • Surgical Centers
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Duchenne Muscular Dystrophy Treatment Industry - Regional Synopsis

APAC Market Statistics

On the basis of geographical analysis, the global Duchenne muscular dystrophy treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is anticipated to account for largest revenue share by 2036, due to high prevalence of musculoskeletal diseases in the region. For instance, according to the World Bank, in India, 51.964% of the total population is male, in 2020. Moreover, the constant development in public healthcare services, backed by rapid economic growth, are anticipated to boost the market growth.

North America Market Analysis

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the high health awareness amongst the population, along with easy access of quality healthcare in the developed nations. Furthermore, rising concerns amongst authorities, regarding rising prevalence of genetic diseases, is also estimated to boost the market growth.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Duchenne Muscular Dystrophy Treatment Landscape

    • Baxter International, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • Novartis AG
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Siemens Healthcare GmbH
    • Pfizer Inc.
    • Becton, Dickinson and Company

In the News

  • June, 2021: Novartis AG, the leading pharmaceutical company for global drug distribution, announced to collaborate with Hewlett Packard Enterprise to expand its portfolio in medical devices production.

  • May, 2018: The Myositis Association (TMA) announced May as Myositis Awareness Month, to spread awareness regarding the autosomal muscular disease. 

Author Credits:  Radhika Pawar


  • Report ID: 3814
  • Published Date: Aug 22, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of duchenne muscular dystrophy treatment is assessed at USD 3.41 billion.

Duchenne Muscular Dystrophy Treatment Market size was valued at USD 3.12 billion in 2023 and is expected to exceed USD 13.3 billion by 2036, expanding at over 11.8% CAGR during the forecast period i.e., between 2024-2036. Increasing incidences of DMD, and the emergence of mutation-specific therapies will boost the market growth.

Asia Pacific industry is anticipated to account for largest revenue share by 2036, due to high prevalence of musculoskeletal diseases in the region.

The major players in the market are Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., and others.
Duchenne Muscular Dystrophy Treatment Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample